Dr. Justin Favaro spoke to LiveLung about new advances in immunotherapy and targeted therapy for lung cancer patients. During his conversation, Dr. Favaro shared new methods of treating Lung Cancer patients.

In addition to Dr. Favaro’s conversation on advances in treating Lunch Cancer. Oncology Specialists of Charlotte is offering Clinical Trials on Non-Small Cell Lung Cancers.

  • A pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard-of-care therapies for the treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure.
  • Patients with a histology-based diagnosis of stage 4 NSCLC, older than 22 years of age and progression on or after receiving platinum-based chemotherapy are eligible for the study.